Gilead Sciences (GILD) is back in focus after a busy stretch, including strong Q4 and 2025 results, rapid take up of HIV prevention drug Yeztugo, and an FDA label expansion for cell therapy Yescarta.

The recent run of earnings, guidance, dividend increase, and the Yescarta label update has coincided with strong momentum, with a 30 day share price return of 24.91% and a 1 year total shareholder return of 53.07% building on a 5 year total shareholder return of 191.72%.

If Gilead’s move has caught your attention, it could be a good moment to see what else is gaining traction in healthcare. You could start with our screener of 25 healthcare AI stocks.

After a 53.07% 1 year total return and with shares now trading slightly above the average analyst price target, the key question is whether Gilead’s 47% implied intrinsic discount still points to mispricing or if the market is already banking on future growth.

Most Popular Narrative: 16.9% Overvalued

Gilead’s most followed narrative pegs fair value at $132.57, which sits below the recent $154.98 close, so you are looking at a valuation gap that still needs explaining.

Disciplined operating expense management and expanded share buybacks backed by strong free cash flow are increasing efficiency, supporting progressively higher operating margins and EPS growth; updated guidance reflects confidence in operating leverage and capital returns.

Curious what kind of revenue run rate, margin profile, and future P/E this narrative is baking in? The model leans on steady growth, richer profitability, and a higher future earnings multiple than the broader biotech peer group. If you want to see exactly how those moving parts line up to justify a higher fair value than past reports, the full narrative lays it out in detail.

Result: Fair Value of $132.57 (OVERVALUED)

However, this hinges on HIV staying as resilient as analysts expect, and on newer oncology and PrEP launches avoiding the regulatory, pricing, and uptake setbacks they worry about.

Another Take: DCF Points To Deep Undervaluation

The 16.9% overvaluation estimate contrasts with our DCF model, which puts fair value at $294.02 per share. With Gilead at $154.98, the DCF view suggests the stock trades at a 47.3% discount. Which perspective do you think better reflects the risks and cash flow profile?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Gilead Sciences for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 53 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own Gilead Sciences Narrative

If you are not on board with these assumptions or prefer to work from your own numbers, you can test the data yourself and Do it your way in under three minutes.

A great starting point for your Gilead Sciences research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

If Gilead has sharpened your focus, do not stop here. The screener can surface other opportunities you might regret overlooking once the market catches on.

• Target quality at a discount by scanning our list of 53 high quality undervalued stocks that pair solid fundamentals with prices that still look reasonable.
• Strengthen your income stream by checking out 13 dividend fortresses, where yields start at 5% and stability is front and center.
• Protect your downside by reviewing 85 resilient stocks with low risk scores, built around companies that score well on resilience and financial risk checks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.